The Failure of Solanezumab - How the FDA Saved Taxpayers Billions

N Engl J Med. 2017 May 4;376(18):1706-1708. doi: 10.1056/NEJMp1701047.
No abstract available

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Antibodies, Monoclonal, Humanized / economics
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Cost Savings
  • Dementia / drug therapy
  • Drug Approval* / legislation & jurisprudence
  • Drug Costs*
  • Humans
  • Randomized Controlled Trials as Topic
  • Treatment Failure
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal, Humanized
  • solanezumab